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Therefore, EGFR signalling in colon cancer is modulated at the
level of receptor capacity, receptor heterodimerization, regulation
of intracellular tyrosine kinase activity, ligand presentation and
by other costimulatory receptor pathways. These mechanisms
have to be considered when therapeutic strategies using EGFR-
inhibition are evaluated.
doi:10.1016/j.ejcsup.2006.04.045
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Colorectal cancer is one of the most prevalent cancers world-
wide. Whereas surgery is the basis of therapy, chemo- and/or
radiotherapy are used frequently to reduce local and distant
recurrences. Many prognostic factors have been defined, with
only the UICC classification being relevant for therapeutic deci-
sions at present. The prognosis for an individual patient, how-
ever, still cannot be sufficiently predicted. Therefore, many
patients will receive radio-/chemotherapy that do not benefit
from this treatment. Other patients might not receive radio-/che-
motherapy as they are judged to be at a low risk for recurrence,
but will develop recurrent disease. Better prognostic factors are
therefore needed, in order to individualize the therapeutic strat-
egy. As recurrences after complete tumor removal are most likely
caused by disseminated tumor cells, it seems to be a logical
approach to develop methods to detect these cells. Ideally,
patients in whom tumor cells can be detected should have a
worse prognosis and should therefore benefit from adjuvant
therapeutic strategies. The effect of this therapy should then
become apparent by a reduced detection rate of disseminated
tumor cells. Even though some studies demonstrate a prognostic
relevance of disseminated tumor cells, the prognostic relevance
of these cells is not generally accepted. Due to the heterogeneity
of disseminated tumor cells, demonstration of the mere pres-
ence of these cells will most likely not be an adequate basis
for therapeutic decisions. Molecular characterization of dissemi-
nated tumor cells and/or of the primary tumor might be a more
successful approach in this respect. The clinical relevance of
molecular staging for therapeutic decisions, however, has still
to be proven in well designed clinical trials.
doi:10.1016/j.ejcsup.2006.04.046
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Bisphosphonates have been used extensively for more than 3 dec-
ades to inhibit osteoclastic activity in a variety of benign and
malignant diseases characterized by increased bone resorption.
Due to the bisphosphonate moiety, these compounds bind avidly
to bone mineral and accumulate at sites of active bone turnover.
During bone resorption they are released and ingested by osteo-
clasts via fluid-phase endocytosis. The nitrogen-containing bis-
phosphonates (N-BPs) inhibit a key intracellular enzyme in the
mevalonate pathway, farnesyl pyrophosphate synthase, thereby
reducing prenylation of small GTPase signalling proteins that
are essential for osteoclast function and survival. Consequently,
bone resorption is impaired and osteoclast apoptosis is induced.
Zoledronic acid (Zometa) is a novel compound which retains
the bisphosphonate ‘‘bone hook’’ and possesses a heterocyclic
imidazole substituent containing 2 nitrogen atoms. X-ray crystal-
lography studies with human farnesyl pyrophosphate synthase
have shown that the zoledronic acid molecule binds with high
affinity to the active site of the enzyme and induces an irrevers-
ible conformational change that prevents further access of sub-
strate. Structure-activity studies with more than 300 novel
compounds identified zoledronic acid as the lead candidate for
clinical development due to its outstanding potency as an inhib-
itor of osteoclastic bone resorption both in vitro and in vivo, and
its excellent in vivo tolerability.
In animal models of breast cancer, prostate cancer, osteosar-
coma and haematological malignancies such as multiple mye-
loma and leukaemia, low doses of zoledronic acid markedly
inhibit osteoclastic activity and thus reduce tumour-induced oste-
olysis and hypercalcaemia. Bone is a rich source of growth factors
which are released during bone resorption and can stimulate
tumour cell proliferation. By inhibiting osteoclastic activity, zoled-
ronic acid reduces the release of tumour growth factors from bone
and thus interrupts this stimulatory cycle. Furthermore, the high
local concentration of bisphosphonate at an osteolytic site may
exert direct cytostatic and apoptotic effects on the tumour cells
in a bone metastasis. Extensive in vitro data show that zoledronic
acid is cytostatic and pro-apoptotic against a variety of human
tumour cell lines. Interestingly, zoledronic acid enhances the effi-
cacy of some cytotoxic drugs in a synergistic manner, especially
when the drugs are administered sequentially rather than con-
comitantly. Apart from these direct effects on tumour cell prolifer-
ation and viability, N-BPs also impair the metastatic behaviour of
tumour cells and modulate the host’s response to neoplastic dis-
ease. In vitro, zoledronic acid potently inhibits tumour cell inva-
sion through extracellular matrix, decreases cell adhesion to
both mineralized and non-mineralized matrices, and disrupts soft
tissue angiogenesis. Preclinical data from a variety of animal
tumour models demonstrate that, in vivo, these effects translate
into reduced tumour load, increased tumour cell apoptosis, and
in some cases delayed disease progression with a corresponding
survival benefit. Although these effects have been predominantly
observed in models of bone metastases in nude mice, emerging
data indicate that zoledronic acid can also inhibit the growth of
primary soft tissue tumours in transgenic animals by a mecha-
nism that apparently involves inhibition of angiogenesis and dis-
rupted macrophage function.
Recently, another intriguing facet has been added to the phar-
macological profile of the N-BPs. It has been known for many
years that these compounds interact with the immune system
to produce an acute phase response in a significant proportion
of patients, especially when administered intravenously, but the
molecular mechanism remained elusive. It is now known that
this effect is caused by inhibition of farnesyl pyrophosphate syn-
thase in monocytes, leading to accumulation of upstream metab-
20 E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 3 –2 6
olites of the mevalonate pathway which trigger proliferation of a
subset of cytotoxic gamma, delta T cells and cytokine release.
Several studies are now in progress investigating whether this
immunomodulatory effect of zoledronic acid can be utilized in
oncology to enhance its therapeutic potential beyond the well
established inhibition of tumour-induced osteolysis.
doi:10.1016/j.ejcsup.2006.04.047
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Background: Non small cell lung cancer (NSCLC) is the leading
cause of cancer related deaths, mostly secondary to diffuse extra-
thoracic spread of the disease in several organs and systems. Bone
metastases (BM) may be present at diagnosis or develop in the fol-
low up, are associated with a worse prognosis, and currently there
are no chemical or biological markers predicting their clinical
onset. Several molecules are potential factors favouring bone dis-
semination by cancer cells, including cell cycle proteins, angioge-
netic factors, extra-cellular matrix proteins and their inhibitors,
serum and plasma proteins implicated in bone resorption mecha-
nisms. Increased levels of some of these molecules (periostin, BSP
and osteopontin) were found in colon, breast and prostate can-
cers. Their role in lung cancer is controversial. Aim of this study
was to investigate the predictive and prognostic value of bone
resorption-related molecules in favouring or modulating the colo-
nisation of bone tissue during haematogenous spread of NSCLC.
Methods: Thirty cases of resected NSCLC which developed BM
(group A – mean follow up time 27.2 months) were matched for
several clinico-pathological parameters (including age, sex, stage
of the disease, histology, differentiation grade, adjuvant therapy)
to 30 cases of resected NSCLC without any metastases (group B –
mean follow up time 75.1 months) and 26 resected NSCLC with
non-bone metastases (group C – mean follow up 21.1 months).
Primary tumor samples were investigated by a standard auto-
mated immunoperoxidase procedure for 10 markers previously
recognized to be involved in bone resorption or metastatization
process (cathepsin K, bone sialoprotein [BSP],VEGF, MMP-2, p53,
RECK, TIMP-1, CD-117, Ki-67 and TRAcP). For statistical analysis,
the staining distribution in tumor cells was assessed by a semi-
quantitative score (0, <10%, 10–50%, >50% positive tumor cells).
Differences among groups were estimated by v2 test, whereas
the prognostic impact of clinico-pathological parameters and
marker expression was evaluated by univariate and multivariate
analyses. An additional series of 120 resected consecutive NSCLC
was also tested for BSP expression prevalence (group D).
Results: Among the different markers investigated, BSP expres-
sion was significantly higher in bone metastatic cases (80%)
compared to 20% and 31% of groups B (non metastatic) and C
(non-bone metastases), respectively (p < 0.001). BSP expression
did not show any difference according to tumor histotype or
any other characteristics. In addition, taking all the three groups
together, or the metastatic groups (groups A and C) alone, BSP
expression was also shown to be related to poor outcome
(p = 0.02 by Mantel–Cox test). None of the other markers was dif-
ferentially expressed within the groups or demonstrated a prog-
nostic impact, both in terms of overall survival and of time
interval to metastases. BSP was further estimated in 120 resected
NSCLCs (M:F ratio 3:1; mean age 67 years; histotype: adenocarci-
nomas 55%, squamous cell carcinoma 39%, others 6%; stages: I
54%, II 17%, III 29%) and a prevalence of 40% observed, without
any statistically significant difference according to histotype or
other clinico-pathological parameters.
Discussion: In this study, we have shown that BSP is signifi-
cantly more expressed in a series of NSCLC metastatic to bone
as compared with matched control groups of NSCLC (metastatic
or non metastatic) which did not progress to bone in the same
period of time. BSP expression was also found to be predictive
of poor prognosis, but not related to the time interval to distant
spread. Moreover, in a large consecutive series of resected NSCLC
we observed a prevalence of BSP protein expression of 40%. Inter-
estingly, this percentage of positivity is intermediate between
that in group A on the one side, and groups B and C on the other.
The biological significance of BSP expression in tumors progress-
ing to bone metastases is not fully understood. The balance of
bone apposition and resorption involves several molecules,
locally produced or possibly blood-born, which act through differ-
ent specific circuits. BSP itself may be powering the effect of bone
resorption and facilitate bone colonisation by tumor cells. In
in vitro models, BSP favoured cancer cell invasiveness through a
linkage with integrins and MMP2. Inhibition of BSP-MMP2 com-
plex was able to block BSP-enhanced invasiveness. Our findings
suggest that in the future NSCLC patients with BSP expression,
may benefit of BSP inhibitors and may also be reasonably good
candidates for preventive treatments (i.e., bone metabolic agents)
in order to block, reduce or delay the osteotropism of cancer cells.
In conclusion, immunohistochemical expression of BSP in resected
NSCLC strongly predicts bone dissemination, and may therefore
be useful in selecting patients for treatments targeted to contrast
bone metastatic spread.
doi:10.1016/j.ejcsup.2006.04.048
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CD133 positive ‘‘Cancer Stem Cells’’ (CSC) have been shown to ini-
tiate and maintain glioblastoma growth. The first aim of our stud-
ies was to further characterize CD133+ cells in gliomas of different
grades with respect to their prospective origin and differentiation
potential. CD133+ cells could be identified in gliomas grade II–IV.
Co-expression of CD133 and Musashi-1 indicated a neural stem
cell character of CD133+ cells. Expression of both markers was
clearly grade dependent with up to 20% of cells being CD133+ in
GBM. Under different culture conditions, CD133+ cells isolated
from gliomas lost CD133 expression and started expression of
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